Author

G. G. Luo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:protein sequence· 1

Frequent Co-Authors

A. Khan· 1 shared A. Ojha· 1 shared B. D. Quinlan· 1 shared B. H. Bodnar· 1 shared F.-Z. Meng· 1 shared G. Zhong· 1 shared H. Choe· 1 shared H. Mou· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. Khan

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Epigallocatechin Gallate from Green Tea Effectively Blocks Infection of SARS-CoV-2 and New Variants by Inhibiting Spike Binding to ACE2 Receptor

J. Liu, B. H. Bodnar, F.-Z. Meng, A. Khan, X. Wang, G. G. Luo, S. Saribas, T. Wang, S. C. Lohani, P. Wang, Z. Wei, J. Luo, L. Zhou, J. Wu, Q. Li, , W. Ho

This study shows that EGCG from green tea inhibits SARS-CoV-2 and its variants by blocking spike protein binding to ACE2 receptors.

bioRxiv · Mar 17, 2021Microbiology

An engineered receptor-binding domain improves the immunogenicity of multivalent SARS-CoV-2 vaccines

B. D. Quinlan, W. Li, H. Mou, L. Zhang, J. Chang, S. Peng, A. Ojha, R. Tavora, M. S. Parcells, G. G. Luo, W. Li, G. Zhong, H. Choe, M. Farzan

This paper shows that an engineered RBD with glycosylation sites improves immunogenicity and expression efficiency in SARS-CoV-2 vaccines.

bioRxiv · Nov 18, 2020Microbiology